文献速递骨质疏松与代谢性骨病

人类免疫缺陷病毒感染者的骨密度降低:患病率及危险因素的荟萃分析

Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
PubMed 文献 · Osteoporos Int · 2017-11-20

该荟萃分析纳入1989至2015年六个数据库的文献,评估HIV感染者及抗逆转录病毒治疗(ART)者骨量减少/骨质疏松的患病率。HIV感染者和ART治疗者骨量减少/骨质疏松的患病率均显著高于对照,合并比值比(OR)在腰椎和髋部分别为2.4和2.6(HIV感染者)及2.8和3.4(ART治疗者)。感染后或ART启动后第一年内骨丢失的证据尚属初步。

要点

  • HIV感染者骨量减少/骨质疏松风险约为对照的2倍以上,腰椎OR=2.4、髋部OR=2.6。
  • ART治疗者风险更高,腰椎OR=2.8、髋部OR=3.4,均显著高于对照。
  • 替诺福韦治疗者低骨密度比例52.6% vs 对照42.7%,差异未达统计学显著(p=0.248)。

核心结论

  • HIV感染者和ART治疗者骨量减少/骨质疏松的患病率约为对照的2倍。
  • 关于HIV感染后或ART启动后第一年内骨丢失的证据尚属初步。

研究设计与样本

  • 系统检索1989至2015年六个数据库的英文全文文献。
  • 纳入年龄≥18岁、采用双能X线吸收法测量骨密度的HIV感染者研究。
  • 排除无对照组报告骨量减少/骨质疏松患病率或未报告骨密度/T值的文献。
  • 共纳入21项横断面研究和8项纵向研究。

主要发现

  • HIV感染者骨量减少/骨质疏松风险显著高于对照:腰椎OR=2.4(95%CI 2.0–2.8),髋部OR=2.6(95%CI 2.2–3.0)。
  • ART治疗者风险显著高于对照:腰椎OR=2.8(95%CI 2.0–3.8),髋部OR=3.4(95%CI 2.5–4.7)。
  • 蛋白酶抑制剂(PI)治疗者发生骨量减少/骨质疏松的OR=1.3(95%CI 1.0–1.7),与对照相比。
  • 替诺福韦治疗者低骨密度比例52.6%,对照42.7%,差异未达统计学显著(p=0.248)。
  • HIV感染者、PI治疗者、替诺福韦治疗者与对照之间,腰椎、股骨颈或全髋骨密度自基线至随访的变化百分比无显著差异。

关键数值与推荐

  • 高龄、骨折史、低体重指数、低体重、西班牙裔或白人、低睾酮水平、吸烟、低CD4细胞计数、脂肪营养不良、低脂肪量及低瘦体重与低骨密度相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 关于HIV感染后第一年内骨丢失的证据尚属初步。
  • 关于ART启动后第一年内骨丢失的证据尚属初步。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: A meta-analysis was conducted to evaluate the prevalence of osteopenia/osteoporosis in human immunodeficiency virus (HIV)-infected individuals. The prevalence of osteopenia/osteoporosis in HIV-infected and antiretroviral therapy (ART)-treated individuals was significantly higher than respective controls. Evidence regarding bone loss within first year of HIV infection or ART initiation was preliminary. PURPOSE: The aim of the study is to systematically review published literature on the prevalence of osteopenia/osteoporosis and its associated risk factors in HIV-infected individuals. METHODS: A literature search was conducted from 1989 to 2015 in six databases. Full text, English articles on HIV-infected individuals ≥ 18 years, which used dual X-ray absorptiometry to measure BMD, were included. Studies were excluded if the prevalence of osteopenia/osteoporosis was without a comparison group, and the BMD/T-score were not reported. RESULTS: Twenty-one cross sectional and eight longitudinal studies were included. The prevalence of osteopenia/osteoporosis was significantly higher in both HIV-infected [odds ratio (OR) = 2.4 (95%Cl: 2.0, 2.8) at lumbar spine, 2.6 (95%Cl: 2.2, 3.0) at hip] and ART-treated individuals [OR = 2.8 (95%Cl: 2.0, 3.8) at lumbar spine, 3.4 (95%Cl: 2.5, 4.7) at hip] when compared to controls. PI-treated individuals had an OR of 1.3 (95%Cl: 1.0, 1.7) of developing osteopenia/osteoporosis compared to controls. A higher proportion of tenofovir-treated individuals (52.6%) had lower BMD compared to controls (42.7%), but did not reach statistical significance (p = 0.248). No significant difference was found in the percent change of BMD at the lumbar spine, femoral neck, or total hip from baseline to follow-up between HIV-infected, PI-treated, tenofovir-treated, and controls. Older age, history of bone fracture, low BMI, low body weight, being Hispanic or Caucasian, low testosterone level, smoking, low CD4 cell count, lipodystrophy, low fat mass, and low lean body mass were associated with low BMD. CONCLUSIONS: The prevalence of osteopenia/osteoporosis in HIV-infected and antiretroviral therapy (ART)-treated individuals was two times more compared to controls. However, evidence concerning bone loss within the first year of HIV infection and ART initiation was preliminary.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Goh SSL, Lai PSM, Tan ATB, et al. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int. 2017. PMID: 29159533. doi:10.1007/s00198-017-4305-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。